Sign In
Buy UBX
$0.200
+0 (+0%)
At Close: Oct 10, 2025
UBX Tanzania Deepens Partnership with ACI Worldwide to Power the Next Phase of the Nation's Digital Economy
01:00am, Thursday, 21'st May 2026
OMAHA, Neb. & DAR ES SALAAM, Tanzania--(BUSINESS WIRE)--ACI Worldwide (NASDAQ: ACIW), an original innovator in global payments technology, today announced the extension of its long-standing partnershi
UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting
08:00am, Thursday, 01'st May 2025
SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases o
UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates
04:30pm, Tuesday, 22'nd Apr 2025
SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of ag
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study
12:55pm, Tuesday, 25'th Mar 2025
UNITY Biotechnology stock loses 29% as the mid-stage DME study of the lead candidate, UBX1325, fails to achieve statistical significance for the primary goal.
Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls
11:26am, Monday, 24'th Mar 2025
Unity Biotechnology, Inc. UBX stock plummeted on Monday after the company released results from its latest study.
UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema
07:01am, Monday, 24'th Mar 2025
Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325 was non-inferior to aflibercept at week 24 (>90% confidenc
SOUTH SAN FRANCISCO, Calif., March 23, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse disease
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
04:30pm, Friday, 07'th Mar 2025
SAN FRANCISCO, March 07, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, to
UNITY Biotechnology Reports Granting of New Employment Inducement Award
04:10pm, Tuesday, 07'th Jan 2025
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases
UNITY Biotechnology Announces Appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer
08:00am, Monday, 06'th Jan 2025
SAN FRANCISCO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, toda
UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates
04:30pm, Monday, 04'th Nov 2024
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of agi
UNITY Biotechnology (UBX) Upgraded to Buy: Here's What You Should Know
01:01pm, Friday, 09'th Aug 2024
UNITY Biotechnology (UBX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates
04:30pm, Tuesday, 06'th Aug 2024
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of agi
UNITY Biotechnology Announces Appointment of Alicia Tozier as Chief Strategy Officer
08:00am, Monday, 22'nd Jul 2024
SAN FRANCISCO, July 22, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, toda
All You Need to Know About UNITY Biotechnology (UBX) Rating Upgrade to Buy
01:01pm, Friday, 17'th May 2024
UNITY Biotechnology (UBX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
